trial · primary record
Eribulin Mesylate
Advanced Urothelial Carcinoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 168 |
| Primary completion | 2027-07-09 |
| Primary endpoint | Maximum Tolerated Dose (MTD) of Eribulin Mesylate for Patients Who Have Received a Tubulin-inhibitor for the Recurrent/Advanced Disease (Phase I) |
| Registry ID | NCT00365157 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:33:06.579Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT00365157
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.